Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.

ABSTRACT:

Background and objective

Pexidartinib is a novel oral small-molecule inhibitor that selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation. It is approved in the United States for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. Pexidartinib in vitro data indicate the potential for absorption- and metabolism-related drug-drug interactions (DDIs). The objective was to present a comprehensive DDI risk assessment of agents that can impact pexidartinib exposure by altering its absorption and metabolism potentially affec

SUBMITTER: Zahir H 

PROVIDER: S-EPMC9652259 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature